Pattern of inappropriate antibiotic use among hospitalized patients in Pakistan: a longitudinal surveillance and implications.


Journal

Antimicrobial resistance and infection control
ISSN: 2047-2994
Titre abrégé: Antimicrob Resist Infect Control
Pays: England
ID NLM: 101585411

Informations de publication

Date de publication:
2019
Historique:
received: 10 05 2019
accepted: 11 11 2019
entrez: 27 11 2019
pubmed: 27 11 2019
medline: 18 7 2020
Statut: epublish

Résumé

The inappropriate use of antibiotics in hospitals increases resistance, morbidity, and mortality. Little is currently known about appropriate antibiotic use among hospitals in Lahore, the capital city of Pakistan. Longitudinal surveillance was conducted over a period of 2 months among hospitals in Lahore, Pakistan. Antibiotic treatment was considered inappropriate on the basis of a wrong dosage regimen, wrong indication, or both based on the British National Formulary. A total of 2022 antibiotics were given to 1185 patients. Out of the total prescribed, approximately two-thirds of the study population (70.3%) had at least one inappropriate antimicrobial. Overall, 27.2% of patients had respiratory tract infections, and out of these, 62.8% were considered as having inappropriate therapy. Cephalosporins were extensively prescribed among patients, and in many cases, this was inappropriate (67.2%). Penicillins were given to 283 patients, out of which 201 (71.0%) were prescribed for either the wrong indication or dosage or both. Significant variations were also observed regarding inappropriate prescribing for several antimicrobials including the carbapenems (70.9%), aminoglycosides (35.8%), fluoroquinolones (64.2%), macrolides (74.6%) and other antibacterials (73.1%). Educational interventions, institutional guidelines, and antimicrobial stewardship programs need to be developed to enhance future appropriate antimicrobial use in hospitals in Pakistan. Policies by healthcare and Government officials are also needed to minimize inappropriate antibiotic use.

Sections du résumé

Background
The inappropriate use of antibiotics in hospitals increases resistance, morbidity, and mortality. Little is currently known about appropriate antibiotic use among hospitals in Lahore, the capital city of Pakistan.
Methods
Longitudinal surveillance was conducted over a period of 2 months among hospitals in Lahore, Pakistan. Antibiotic treatment was considered inappropriate on the basis of a wrong dosage regimen, wrong indication, or both based on the British National Formulary.
Results
A total of 2022 antibiotics were given to 1185 patients. Out of the total prescribed, approximately two-thirds of the study population (70.3%) had at least one inappropriate antimicrobial. Overall, 27.2% of patients had respiratory tract infections, and out of these, 62.8% were considered as having inappropriate therapy. Cephalosporins were extensively prescribed among patients, and in many cases, this was inappropriate (67.2%). Penicillins were given to 283 patients, out of which 201 (71.0%) were prescribed for either the wrong indication or dosage or both. Significant variations were also observed regarding inappropriate prescribing for several antimicrobials including the carbapenems (70.9%), aminoglycosides (35.8%), fluoroquinolones (64.2%), macrolides (74.6%) and other antibacterials (73.1%).
Conclusion
Educational interventions, institutional guidelines, and antimicrobial stewardship programs need to be developed to enhance future appropriate antimicrobial use in hospitals in Pakistan. Policies by healthcare and Government officials are also needed to minimize inappropriate antibiotic use.

Identifiants

pubmed: 31768252
doi: 10.1186/s13756-019-0649-5
pii: 649
pmc: PMC6873729
doi:

Substances chimiques

Anti-Bacterial Agents 0

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

188

Informations de copyright

© The Author(s). 2019.

Déclaration de conflit d'intérêts

Competing interestsThe authors declare that they have no competing interests.

Références

Antimicrob Resist Infect Control. 2017 Apr 28;6:41
pubmed: 28465825
Pak J Pharm Sci. 2017 Jul;30(4(Suppl.)):1483-1489
pubmed: 29044002
Lancet Infect Dis. 2013 Dec;13(12):1057-98
pubmed: 24252483
PLoS One. 2017 Dec 21;12(12):e0189621
pubmed: 29267306
Hosp Pract (1995). 2019 Feb;47(1):53-58
pubmed: 29757036
Clin Microbiol Infect. 2014 Oct;20(10):963-72
pubmed: 25039787
Pharm World Sci. 2002 Oct;24(5):188-95
pubmed: 12426963
Infect Control Hosp Epidemiol. 2015 Aug;36(8):949-56
pubmed: 25998898
Hosp Pract (1995). 2018 Aug;46(3):97-102
pubmed: 29521136
Expert Rev Anti Infect Ther. 2017 Jul;15(7):713-721
pubmed: 28425828
Int J Clin Pharm. 2015 Jun;37(3):452-6
pubmed: 25832678
Clin Infect Dis. 2007 Jan 15;44(2):159-77
pubmed: 17173212
Hosp Pract (1995). 2017 Oct;45(4):143-149
pubmed: 28657382
Arch Dis Child. 2013 Sep;98(9):720
pubmed: 23852999
PLoS One. 2016 Feb 26;11(2):e0149929
pubmed: 26919465
JAMA. 2016 May 3;315(17):1864-73
pubmed: 27139059
Hosp Pract (1995). 2018 Aug;46(3):128-136
pubmed: 29652559
Lancet. 2016 Jan 9;387(10014):188-98
pubmed: 26603919
Pediatr Infect Dis J. 2019 Feb;38(2):122-126
pubmed: 29677085
Soc Sci Med. 2003 Aug;57(4):733-44
pubmed: 12821020
MMWR Morb Mortal Wkly Rep. 2014 Mar 7;63(9):194-200
pubmed: 24598596
Intern Med J. 2014 Mar;44(3):240-6
pubmed: 24372683
Expert Rev Anti Infect Ther. 2015 May;13(5):665-80
pubmed: 25813839
Soc Sci Med. 2001 Oct;53(7):831-44
pubmed: 11522132
PLoS One. 2016 Mar 22;11(3):e0152020
pubmed: 27002977
Expert Rev Anti Infect Ther. 2019 Apr;17(4):285-293
pubmed: 30755077
Lancet Infect Dis. 2018 Oct;18(10):1066-1067
pubmed: 30303099
Health Bull (Edinb). 1999 Mar;57(2):128-33
pubmed: 12811903
Int J Infect Dis. 2010 Jan;14(1):e55-61
pubmed: 19487149
Clin Microbiol Infect. 2017 Nov;23(11):812-818
pubmed: 28712667
Arch Intern Med. 2003 Apr 28;163(8):972-8
pubmed: 12719208
Expert Rev Anti Infect Ther. 2019 Jul;17(7):535-546
pubmed: 31257952

Auteurs

Zikria Saleem (Z)

1School of Pharmaceutical Sciences, Universiti Sains Malaysia, Gelugor, Malaysia.
2Hamdard Institute of Pharmaceutical Sciences, Hamdard University, Islamabad, Pakistan.

Hamid Saeed (H)

3University College of Pharmacy, University of the Punjab, Lahore, Pakistan.

Mohamed Azmi Hassali (MA)

1School of Pharmaceutical Sciences, Universiti Sains Malaysia, Gelugor, Malaysia.

Brian Godman (B)

1School of Pharmaceutical Sciences, Universiti Sains Malaysia, Gelugor, Malaysia.
Division of Clinical Pharmacology, Karolinska University Hospital Huddinge, Karolinska Institute, Stockholm, Sweden.
5Strathclyde Institute of Pharmacy and Biomedical Sciences, Strathclyde University, Glasgow, UK.
6Health Economics Centre, University of Liverpool Management School, Liverpool, UK.

Usama Asif (U)

Medical Centre, Agha Khan University Hospital, Karachi, Pakistan.

Mahrukh Yousaf (M)

Medical Centre, Agha Khan University Hospital, Karachi, Pakistan.

Zakiuddin Ahmed (Z)

Ripha Institute of Healthcare Improvement & Safety, Ripha University, Islamabad, Pakistan.

Humayun Riaz (H)

Rashid Latif College of Pharmacy, Lahore, Pakistan.

Syed Atif Raza (SA)

3University College of Pharmacy, University of the Punjab, Lahore, Pakistan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH